Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Go back to Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 308.25 -4.53 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $312.78 | 52 Week High | $109.10 | |||
| Open | $319.34 | 52 Week Low | $31.38 | |||
| Day High | $319.34 | P/E | N/A | |||
| Day Low | $307.78 | EPS | $-1.45 | |||
| Volume | 79,706 | |||||
